Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) major shareholder Global Strategic Fund I. Venbio purchased 416,666 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were acquired at an average price of $12.00 per share, for a total transaction of $4,999,992.00. Following the completion of the purchase, the insider now directly owns 1,936,637 shares of the company’s stock, valued at $23,239,644. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Artiva Biotherapeutics Price Performance
Shares of ARTV stock opened at $11.80 on Thursday. Artiva Biotherapeutics, Inc. has a fifty-two week low of $11.71 and a fifty-two week high of $16.00.
Further Reading
- Five stocks we like better than Artiva Biotherapeutics
- Airline Stocks – Top Airline Stocks to Buy Now
- Food Processing Company Stock Gets Fried by Recall: Time to Buy
- ETF Screener: Uses and Step-by-Step Guide
- Entertainment Stock Offers A Rare and Tempting Entry Opportunity
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Will China’s Interest Rate Cuts Ignite a Rally for This Stock?
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
